Time course of antiproteinuric effect of aliskiren in arterial hypertension associated with type 2 diabetes and microalbuminuria

被引：0
|
作者：
Fogari, R.
Mugellini, A.
Zoppi, A.
Preti, P.
Maffioli, P.
Perrone, T.
Derosa, G.
机构：
来源：
EXPERT OPINION ON PHARMACOTHERAPY | 2018年 / 19卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：X / XI
页数：2
相关论文
共 50 条
  • [1] Time Course of Antiproteinuric Effect of Aliskiren in Arterial Hypertension Associated With Type 2 Diabetes and Microalbuminuria
    Fogari, Roberto
    Mugellini, Amedeo
    Zoppi, Annalisa
    Preti, Paola
    Maffioli, Pamela
    Perrone, Tiziano
    Derosa, Giuseppe
    DIABETES, 2013, 62 : A143 - A143
  • [2] Time course of antiproteinuric effect of aliskiren in arterial hypertension associated with type 2 diabetes and microalbuminuria (Publication with Expression of Concern. See vol. 19, 2018)
    Fogari, Roberto
    Mugellini, Amedeo
    Zoppi, Annalisa
    Preti, Paola
    Maffioli, Pamela
    Perrone, Tiziano
    Derosa, Giuseppe
    EXPERT OPINION ON PHARMACOTHERAPY, 2013, 14 (04) : 371 - 384
  • [3] Time course of the antiproteinuric and the antihypertensive effect of aliskiren in patients with type 2 diabetes and albuminuria
    Persson, F.
    Rossing, P.
    Schjodt, K. J.
    Juhl, T. R.
    Tarnow, L.
    Stehouwer, C. D. A.
    Schalkwijk, C.
    Boomsma, F.
    Frandsen, E.
    Parving, H.-H.
    DIABETOLOGIA, 2007, 50 : S460 - S460
  • [4] MICROALBUMINURIA, ARTERIAL HYPERTENSION AND TYPE 2 DIABETES MELLITUS
    Hoxha, V.
    Petrela, E.
    Zaimi, E.
    Hasani, E.
    Laci, I.
    Cela, L.
    JOURNAL OF HYPERTENSION, 2010, 28 : E290 - E290
  • [5] ANTIPROTEINURIC EFFECT OF RASILEZ (ALISKIREN) IN HYPERTENSIVE/NORMOTENSIVE TYPE 2 DIABETES ADDED ON TO ACEI BASE TREATMENT
    Nordin, S.
    Izani, W. M.
    Bebakar, W. M. Wan
    Zahiruddin, W. M.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2014, 106 : S127 - S129
  • [6] Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes
    Persson, F.
    Rossing, P.
    Schjoedt, K. J.
    Juhl, T.
    Tarnow, L.
    Stehouwer, C. D. A.
    Schalkwijk, C.
    Boomsma, F.
    Frandsen, E.
    Parving, H-H
    KIDNEY INTERNATIONAL, 2008, 73 (12) : 1419 - 1425
  • [7] Optimal antiproteinuric dose of aliskiren in type 2 diabetes mellitus: a randomised crossover trial
    F. Persson
    P. Rossing
    H. Reinhard
    T. Juhl
    C. D. A. Stehouwer
    C. Schalkwijk
    A. H. J. Danser
    F. Boomsma
    E. Frandsen
    H.-H. Parving
    Diabetologia, 2010, 53 : 1576 - 1580
  • [8] Optimal antiproteinuric dose of aliskiren in type 2 diabetes mellitus: a randomised crossover trial
    Persson, F.
    Rossing, P.
    Reinhard, H.
    Juhl, T.
    Stehouwer, C. D. A.
    Schalkwijk, C.
    Danser, A. H. J.
    Boomsma, F.
    Frandsen, E.
    Parving, H. -H.
    DIABETOLOGIA, 2010, 53 (08) : 1576 - 1580
  • [9] Antiproteinuric effects of losartan in normotensive patients with Type 2 diabetes mellitus and microalbuminuria.
    Zandbergen, AAM
    Baggen, MGA
    Lamberts, SWJ
    Bootsma, AH
    de Zeeuw, D
    Akkerhuis, KM
    Ouwendijk, RJT
    DIABETOLOGIA, 2003, 46 : A338 - A338
  • [10] Increased renal arterial resistance predicts the course of renal function in type 2 diabetes with microalbuminuria
    Nosadini, R
    Velussi, M
    Brocco, E
    Abaterusso, C
    Carraro, A
    Piarulli, F
    Morgia, G
    Satta, A
    Faedda, R
    Abhyankar, A
    Luthman, H
    Tonolo, G
    DIABETES, 2006, 55 (01) : 234 - 239
12345